NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense (NASDAQ:NRSN) will participate in a Roth Capital Partners KOL webinar titled “A Quest to Outrun ALS” on July 8, 2026, at 11:00 a.m. ET.

Rhea-AI Summary

NeuroSense (NASDAQ:NRSN) will participate in a Roth Capital Partners KOL webinar titled “A Quest to Outrun ALS” on July 8, 2026, at 11:00 a.m. ET.

Experts will discuss ALS treatment needs, trial endpoints, and NeuroSense’s PrimeC and its Phase 3 PARAGON study.

Argus Jul 6 session 1 alert

-1.69% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – NRSN

$25.56M Mkt Cap at Peak Alert

On Jul 6, the day this news came out, NRSN closed 1.69% below the previous close.

Data tracked by StockTitan Argus for the Jul 6 session.

Key Figures

Webinar date: July 8, 2026 Webinar time: 11:00 a.m. Eastern Time Trial phase: Phase 3

Webinar date

July 8, 2026

Scheduled KOL webinar on ALS treatment and PrimeC

Webinar time

11:00 a.m. Eastern Time

Start time for Roth-hosted ALS KOL webinar

Trial phase

Phase 3

Pivotal PARAGON ALS study design discussion

Historical Context

5 past events · Latest: Jun 29

5 events

1. Jun 29

   Phase 2b ALS data

   24h Move

   -6.3%

   Phase 2b PARADIGM ALS study of PrimeC met primary biomarker endpoint.

2. Jun 25

   Alzheimer's biomarker data

   24h Move

   -0.1%

   Phase 2 RoAD proof-of-concept study showed favorable biomarker changes and safety.

3. Jun 22

   ALS community webinar

   24h Move

   -1.9%

   Online event to review emerging PrimeC ALS data with patient community group.

4. Jun 11

   South Korea ALS patent

   24h Move

   +1.1%

   South Korean patent grant covering PrimeC composition and ALS use through 2042.

5. Jun 09

   Japan composition patent

   24h Move

   -0.2%

   Japanese patent granted for PrimeC’s novel composition and synchronized delivery.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

als, clinical trial endpoints, standard of care, fda accelerated approval

4 terms

als medical

"A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)."

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

clinical trial endpoints medical

"to the clinical trial endpoints that may better capture disease progression."

Clinical trial endpoints are the specific results researchers measure to decide if a medical treatment works or is safe, such as how long patients live, whether symptoms improve, or how a lab value changes. For investors, endpoints are the goalposts that determine a trial’s success or failure, influence regulatory approval chances and market size, and help predict a drug’s commercial value and risk—clear, meaningful endpoints make outcomes easier to interpret and value.

standard of care medical

"positioned - mechanistically and clinically - relative to the current standard of care"

Standard of care is the accepted medical treatment or clinical approach that most qualified doctors would use for a given condition today, based on available evidence, guidelines and common practice. For investors, it acts like the baseline product customers expect: a new therapy or device must match or improve on the standard of care to win market share, gain reimbursement and limit legal or regulatory risk.

fda accelerated approval regulatory

"aim to demonstrate on the path toward potential FDA accelerated approval"

A regulatory pathway that allows a drug or biologic for a serious or life-threatening condition to be approved based on a surrogate or intermediate measure that is reasonably likely to predict real clinical benefit, with the requirement that confirmatory trials are completed after approval. Think of it like a provisional pass that lets a product reach patients and the market sooner while additional studies must prove the promised benefit; for investors, it can speed revenue and increase regulatory risk until confirmatory results are confirmed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging therapeutic approaches with the potential to change the course of the disease.

The live webinar will take place on Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time and will be hosted by Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, who covers the biotechnology sector. The discussion will feature Professor Jeremy Shefner, M.D., Ph.D., Chair of Neurology at Barrow Neurological Institute and Co-Founder of the Northeast ALS Consortium (NEALS), together with Alon Ben-Noon, Chief Executive Officer of NeuroSense.

To join the conversation, register in advance here.

The webinar will explore the most pressing questions in ALS drug development today - from the persistent unmet needs that continue to challenge patients and clinicians, to the clinical trial endpoints that may better capture disease progression. The discussion will also examine how NeuroSense's PrimeC is positioned - mechanistically and clinically - relative to the current standard of care, what the pivotal Phase 3 PARAGON study will aim to demonstrate on the path toward potential FDA accelerated approval, and PrimeC's longer-term commercial opportunity within an evolving ALS treatment landscape.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatment-a-quest-to-outrun-als-302818300.html

SOURCE NeuroSense

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the Roth KOL webinar on the future of ALS treatment featuring NeuroSense (NRSN)?

The webinar is a Roth Capital Partners hosted KOL event on ALS treatments, featuring NeuroSense and experts. It will cover unmet ALS needs, clinical trial endpoint design, and how PrimeC may fit within the evolving treatment landscape for amyotrophic lateral sclerosis.

When is the NeuroSense (NRSN) ALS webinar "A Quest to Outrun ALS" scheduled?

The live NeuroSense ALS webinar is scheduled for Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time. Hosted by Roth Capital Partners, it will discuss ALS treatment challenges, drug development questions, and the positioning of PrimeC in current and future care.

Who are the key speakers at the NeuroSense (NRSN) ALS KOL webinar?

Key speakers include Prof. Jeremy Shefner, Chair of Neurology at Barrow Neurological Institute, and Alon Ben-Noon, NeuroSense’s CEO. Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, will host and moderate the ALS-focused discussion.

What ALS topics will be discussed at the July 8, 2026 NeuroSense (NRSN) webinar?

The webinar will discuss current ALS treatment options, persistent unmet medical needs, and trial endpoint design. It will also explore emerging therapeutic approaches and how PrimeC’s mechanism and clinical profile compare with the current standard of care for ALS patients.

How will the NeuroSense (NRSN) webinar address PrimeC and the Phase 3 PARAGON ALS study?

The discussion will examine PrimeC’s mechanistic and clinical positioning relative to existing ALS therapies. According to NeuroSense, it will also outline what the pivotal Phase 3 PARAGON study aims to demonstrate toward potential FDA accelerated approval and PrimeC’s longer-term commercial opportunity.

How can investors register for the NeuroSense (NRSN) ALS KOL webinar?

Investors can join the NeuroSense ALS webinar by registering in advance through the provided registration link. The event, hosted by Roth Capital Partners, offers access to expert views on ALS drug development, clinical endpoints, and PrimeC’s potential role in the treatment landscape.